Cargando…
Research Participant Interest in Alzheimer’s Disease Biomarker Disclosure
Researchers can characterize the pathophysiological progression of Alzheimer’s disease (AD) even in the absence of symptoms. As we better understand the role of biomarker accumulation in the clinical manifestation of AD, disclosing personal biomarker information will become increasingly relevant. Ye...
Autores principales: | Erickson, Claire, Chin, Nathaniel, Gleason, Carey, Johnson, Sterling, Clark, Lindsay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7740391/ http://dx.doi.org/10.1093/geroni/igaa057.3251 |
Ejemplares similares
-
Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to know
por: Erickson, Claire M., et al.
Publicado: (2021) -
Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society
por: Erickson, Claire M., et al.
Publicado: (2022) -
The importance of the dyad: Participant perspectives on sharing biomarker results in Alzheimer's disease research
por: Ketchum, Fred B., et al.
Publicado: (2023) -
Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing
por: Ketchum, Fred B., et al.
Publicado: (2022) -
Feasibility of virtual Alzheimer's biomarker disclosure: Findings from an observational cohort
por: Erickson, Claire M., et al.
Publicado: (2023)